Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: Safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries
The Journal of Rheumatology, 10/20/2010
Clinical Article
Gibofsky A et al. – The RADIUS registries provide a better understanding of the safety of etanercept in patients with RA in the US practice setting.
Methods- Adults ? 18 years of age who fulfilled 1987 American Rheumatism Association criteria for RAwere eligible for enrollment in 2 prospective, 5-year, multicenter, observational registries
- RADIUS 1 (Rheumatoid Arthritis DMARD Intervention and Utilization Study) enrolled patients with RA who required change in treatment [either an addition or a switch of a biologic or nonbiologic disease-modifying antirheumatic drug (DMARD)]
- In RADIUS 2, patients with RA required to start etanercept therapy at entry
- Patients seen at frequency determined by their rheumatologist
- SAE, SIE, and EMI occurred at rates comparable to those seen in clinical trials
- No unexpected safety signals were observed
- Rates for SAE, SIE, and EMI in etanercept-treated patients comparable to rates observed in patients receiving methotrexate monotherapy and did not increase with greater exposure to etanercept therapy
